A recent Gastroenterology digest,
as sent to subscribers

Study Type: Preclinical experimental study using single-cell RNA sequencing, immunostaining, and murine models

Key Question: Do oncogenic mucins (oncoMUCs) drive immunosuppression in pancreatic ductal adenocarcinoma and can targeting them enhance KRAS inhibitor efficacy?

Key Findings:

• OncoMUC4/16 subpopulations increased after stage IIA/B and correlated with poor survival (P=0.00013)
• Deletion of oncoMUCs reduced immune checkpoint expression (VISTA, TIM3) and increased CD8+ T-cell infiltration (P=0.0087) in murine models
• Combined oncoMUC targeting (Istradefylline) with KRAS-G12D inhibitor (MRTX1133) reduced tumour burden (P=0.034) compared to KRAS inhibition alone

Clinical Relevance: This suggests a potential combination therapy approach for pancreatic cancer patients, targeting both oncogenic mucins and KRAS mutations to overcome immunosuppression—relevant given limited treatment options for pancreatic adenocarcinoma in NHS practice.

Limitations: Findings are from preclinical models and require validation in human clinical trials before clinical application.

Study Type: Prospective cohort study

Key Question: Does dietary intake of specific fermentable fibres (β-glucan and inulin) reduce Crohn's disease risk in asymptomatic first-degree relatives?

Key Findings:

• Higher β-glucan intake reduced CD risk by 30% (HR 0.70, 95% CI 0.54-0.92) and inulin intake by 32% (HR 0.68, 95% CI 0.49-0.96) over 8.5 years follow-up
• Both fibres were associated with improved gut barrier function (lower lactulose-mannitol ratio) and reduced systemic inflammation markers (CRP, TREM-1)
• Protective effects were strongest in participants with higher baseline Erysipelotrichaceae UCG-003 abundance

Clinical Relevance: This provides evidence for targeted dietary counselling in high-risk CD families, potentially informing NHS prevention strategies and personalised nutrition approaches based on microbiome profiling.

Limitations: Dietary intake estimated from food frequency questionnaires rather than measured objectively, limiting accuracy of exposure assessment.

Study Type: Narrative review

Key Question: Does autoimmune gastritis (AIG) predispose to cardia, gastro-oesophageal junction, and oesophageal cancers beyond its established association with non-cardia gastric adenocarcinoma?

Key Findings:

• Emerging evidence suggests AIG may increase cancer risk beyond the gastric body, extending to cardia/GOJ adenocarcinoma and oesophageal malignancies
• Proposed mechanisms include corpus-predominant atrophy, intestinal metaplasia, and vitamin B12 deficiency creating a carcinogenic microenvironment throughout the stomach-oesophagus continuum
• Current diagnostic challenges and under-recognition of AIG in routine practice may have obscured these associations

Clinical Relevance: UK gastroenterologists should consider broader surveillance strategies for AIG patients, as current focus on gastric body neoplasia may miss junctional and oesophageal cancers.

Limitations: Review synthesises scattered evidence rather than presenting new data, and acknowledges significant diagnostic and epidemiological challenges that limit current understanding.

Study Type: Combined observational cohort study (UK Biobank) with experimental animal research

Key Question: Does physical activity protect against chronic pancreatitis development and progression, and what are the underlying mechanisms?

Key Findings:

• UK Biobank analysis (>500,000 participants) showed regular physical activity independently associated with lower chronic pancreatitis risk across all alcohol intake levels
• Mouse models demonstrated exercise interventions reduced pancreatic injury, fibrosis, and ferroptosis, with resistance exercise providing superior protection
• Mechanistically, muscle-derived extracellular vesicles containing PRDX6 accumulated in inflamed pancreata, dampening immune activation via STING pathway modulation

Clinical Relevance: Challenges current assumptions that physical activity may be harmful in chronic pancreatitis, suggesting exercise interventions could represent a novel therapeutic approach for UK patients with this condition.

Limitations: Observational data cannot prove causation, and translation from mouse models to human therapeutic protocols requires validation studies.

Study Type: Experimental study combining murine models with human cohort validation

Key Question: How do tumour-infiltrating adipocytes influence immune suppression and progression in pancreatic ductal adenocarcinoma?

Key Findings:

• High tumour-infiltrating adipocyte abundance correlated with poorer overall survival and immune suppression in 121 PDAC patients
• Adipocyte-derived metabolite 12,13-DiHOME promotes tumour-associated neutrophil ferroptosis via PPARγ-dependent ferritinophagy signalling
• This pathway increases CXCL2 production, which impairs CD8+ T cell function; genetic or pharmacologic disruption restored antitumour immunity in mouse models

Clinical Relevance: This identifies a novel immunometabolic mechanism explaining why peripancreatic fat invasion worsens PDAC prognosis, potentially offering new therapeutic targets (PPARγ, CXCL2/CXCR2 axis) for improving immunotherapy responses in pancreatic cancer patients.

Limitations: Findings are primarily from murine models with limited validation in human tissue samples.

Study Type: Narrative review

Key Question: What are the shared pathogenic mechanisms between preclinical Crohn's disease and postoperative recurrence that could inform prevention strategies?

Key Findings:

• Up to 70% of patients develop postoperative recurrence within 1 year following ileocolonic resection
• Shared biomarkers across disease onset and recurrence include genetic variants, immune mediators (CXCL9, IL-6), microbial signatures (Faecalibacterium, Ruminococcus), and gut barrier dysfunction markers
• Emerging omics approaches (glycomics, urine metabolomics, high-dimensional immunophenotyping) may improve risk stratification and reveal mechanistic insights

Clinical Relevance: This framework could enable biomarker-guided prevention strategies for both new-onset Crohn's disease and postoperative recurrence, potentially reducing the substantial burden of surgical recurrence in UK IBD services.

Limitations: As a narrative review, it lacks systematic methodology and may be subject to selection bias in included studies.

Study Type: Experimental study with translational validation in IBD patient cohorts

Key Question: What is the role of the endogenous peptide GPR15L in colitis pathogenesis and could it represent a therapeutic target?

Key Findings:

• GPR15L mitigated experimental colitis through antimicrobial effects that shaped gut microbiota towards homeostatic communities, independent of T cell recruitment
• Rectal supplementation with recombinant GPR15L counteracted experimental colitis in animal models
• In IBD patients, decreased GPR15L expression during active inflammation correlated with reduced microbial diversity and was associated with flare-free survival

Clinical Relevance: This identifies a novel host defence mechanism that could inform future IBD therapeutic strategies, particularly relevant given the growing recognition of microbiota's role in IBD management within NHS services.

Limitations: The study relies heavily on experimental colitis models which may not fully recapitulate human IBD pathophysiology.

Study Type: Experimental laboratory study using human and murine liver cancer models

Key Question: Does CPEB4 protein deficiency promote vasculogenic mimicry and resistance to anti-VEGF therapy in hepatocellular carcinoma?

Key Findings:

• CPEB4-deficient HCC tumours showed enhanced vasculogenic mimicry capacity and preserved vascular networks under VEGF blockade, maintaining tumour viability when endothelial vessels were impaired
• CPEB4 loss induced an epithelial-to-mesenchymal transition programme with increased translation of EMT-associated transcripts
• CPEB4-deficient tumours demonstrated reduced hypoxia, apoptosis and necrosis compared to controls

Clinical Relevance: This research may explain why some HCC patients develop resistance to anti-VEGF therapies (sorafenib, lenvatinib, bevacizumab combinations) used in NHS practice, potentially identifying CPEB4 expression as a biomarker for treatment response.

Limitations: Laboratory-based study requiring validation in clinical cohorts to determine real-world relevance to patient outcomes and treatment selection.